Hospital De Sao Francisco Xavier
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Hospital De Sao Francisco Xavier the cardiovascular research team investigates heart failure, heart failure with preserved or mildly reduced ejection fraction and obesity, and the combined impact of type 2 diabetes with hypertension. The studies aim to test new therapies that improve cardiac function, lower hospitalization rates, and reduce overall cardiovascular risk.
- Novel agents targeting cardiac remodeling
- Combination therapies for heart failure with preserved ejection fraction
- Impact of metabolic control on cardiovascular outcomes
- Safety profiling of emerging heart failure medications
Researchers collaborate with local cardiology clinics to ensure patient‑centered trial designs and rapid translation of findings into practice.
Hemic and Lymphatic Diseases
The Hemic and Lymphatic Diseases program focuses on primary immune thrombocytopenia, seeking to evaluate the safety and efficacy of innovative biologics that raise platelet counts and enhance patients’ daily lives.
- Immunomodulatory monoclonal antibodies
- Subcutaneous delivery methods for thrombocytopenia treatment
- Biomarker‑driven patient selection
- Long‑term safety monitoring
The centre emphasizes a patient‑focused approach, aiming to reduce bleeding complications and improve quality of life.
Neoplasms
Research on neoplasms concentrates on metastatic colorectal cancer, comparing different chemotherapy and targeted‑therapy sequences to extend progression‑free survival and boost response rates.
- Optimizing FOLFOX/FOLFIRI regimens
- Integrating panitumumab versus bevacizumab
- RAS‑wildtype patient stratification
- Assessment of long‑term disease control
The goal is to generate evidence that guides personalized treatment pathways for advanced colorectal cancer patients.
Skin and Connective Tissue Diseases
In the Skin and Connective Tissue Diseases division, investigators address acute bacterial skin and skin structure infections across age groups, evaluating single‑dose IV antibiotics to simplify therapy and shorten hospital stays.
- Pediatric dosing strategies
- Single‑dose IV antibiotic efficacy
- Safety in diverse skin infection presentations
- Rapid diagnostic integration
Efforts aim to improve treatment convenience while maintaining high cure rates for bacterial skin infections.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 47 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 47 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Boehringer Ingelheim Espana S.A.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital De Sao Francisco Xavier
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER | F. Hoffmann-La Roche AG | Phase III | Not Recruiting | Jun 2022 | — |
IMP list
lock Showing 1 of 47 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Giredestrant | 2 | Unknown | 2022-06-24 | 2024-01-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.